<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine whether regular aspirin use (&gt; or =75 mg/day) is independently associated with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in community-based patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and no history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Of the type 2 diabetic patients recruited to the longitudinal observational Fremantle <z:mp ids='MP_0002055'>Diabetes</z:mp> Study, 651 (50.3%) with no prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> history at entry between 1993 and 1996 were followed until <z:hpo ids='HP_0011420'>death</z:hpo> or the end of June 2007, representing a total of 7,537 patient-years (mean +/- SD 11.6 +/- 2.9 years) </plain></SENT>
<SENT sid="2" pm="."><plain>Cox proportional hazards modeling was used to determine independent baseline predictors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality including regular aspirin use </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: There were 160 <z:hpo ids='HP_0011420'>deaths</z:hpo> (24.6%) during follow-up, with 70 (43.8%) due to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In Kaplan-Meier survival analysis, there was no difference in either <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in aspirin users versus nonusers (P = 0.52 and 0.94, respectively, by log-rank test) </plain></SENT>
<SENT sid="5" pm="."><plain>After adjustment for significant variables in the most parsimonious Cox models, regular aspirin use at baseline independently predicted reduced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality (hazard ratio [HR] 0.30 [95% CI 0.09-0.95] and 0.53 [0.28-0.98[, respectively; P &lt; or = 0.044) </plain></SENT>
<SENT sid="6" pm="."><plain>In subgroup analyses, aspirin use was independently associated with reduced <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in those aged &gt; or =65 years and men </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Regular low-dose aspirin may reduce <z:hpo ids='HP_0000001'>all</z:hpo>-cause and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality in a primary prevention setting in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo>-cause mortality reductions are greatest in men and in those aged &gt; or =65 years </plain></SENT>
<SENT sid="9" pm="."><plain>The present observational data support recommendations that aspirin should be used in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevention in <z:hpo ids='HP_0000001'>all</z:hpo> but the lowest risk patients </plain></SENT>
</text></document>